Entasis Therapeutics Holdings Inc (ETTX)
US2936141033 - Common Stock
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Six abstracts selected for presentation, including three oral presentations...
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Six abstracts selected for presentation, including three oral presentations
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TMX, HR, MN, MICT, ETTX
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
INVESTIGATION ALERT: Halper Sadeh LLP Investigates FHLT, TVTY, MN, ETTX
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company...
SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ETTX, CDEV, CTEK
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of...
Shareholder Alert: Ademi LLP investigates whether Entasis Therapeutics Holdings Inc. has obtained a Fair Price in its transaction with Innoviva
/PRNewswire/ -- Ademi LLP is investigating Entasis (Nasdaq: ETTX) for possible breaches of fiduciary duty and other violations of law in its transaction with...
SHAREHOLDER ALERT: Weiss Law Investigates Entasis Therapeutics Holdings Inc.
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Entasis Therapeutics...
Innoviva to Acquire Entasis Therapeutics
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cashPrice per share in cash represents a 50% premium...
Innoviva to Acquire Entasis Therapeutics
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conferenceSUL-DUR NDA submission on track...
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR)...
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company...
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today
We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about!
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for...
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused...